Nandrolone decanoate is an injectable anabolic androgenic steroid. It is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Nandrolone cannot be reduced by 5-alpha reductase into DHT and therefore does not have an adverse reaction on the prostate. Instead of DHT, nandrolone metabolizes into dihydronandrolone.
Nandrololone does not convert into estrogens. Nandrolone binds well to androgen receptors and also possesses non-receptor mediated stimulation on muscle growth. Nandrolone decanoate is one of the most potent anabolic steroid sfor muscle growth with an excellent myotrophic activity index 3.29–4.92. Nandrolone up-regulates androgen receptor AR expression in skeletal muscle, thus potentiating the actions of other steroids. Nandrolone does not have alkylation on the 17α-carbon and therefore is not toxic for the liver.
Dosage and administration
Adult dose is 50-100mg intramuscular injection per week.
Male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate.
Carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. Pregnancy, because of masculinization of the fetus. Nephrosis or the nephrotic phase of nephritis.
a) Prepubertal: Phallic enlargement and increased frequency of erections.
b) Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability.
In women: Clitoral enlargement, menstrual irregularities.
In both sexes: Increased or decreased libido.
Drug/Laboratory test interactions
Therapy with nandrolone decanoate may decrease thyroxine-binding globulin resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged. Increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK).